Philip W Kantoff

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1088827/publications.pdf

Version: 2024-02-01

447 papers	67,238 citations	1461 110 h-index	884 249 g-index
465 all docs	465 docs citations	465 times ranked	63971 citing authors

#	Article	IF	Citations
1	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clinical Cancer Research, 2022, 28, 318-326.	3.2	28
2	Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. Molecular Oncology, 2022, 16, 2451-2469.	2.1	8
3	Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer. Oncogene, 2022, 41, 671-682.	2.6	8
4	Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	22
5	Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. Prostate, 2022, , .	1.2	3
6	The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. JNCI Cancer Spectrum, 2022, 6, .	1.4	6
7	The Impact of PIK3R1 Mutations and Insulinâ€“PI3Kâ€“Glycolytic Pathway Regulation in Prostate Cancer. Clinical Cancer Research, 2022, 28, 3603-3617.	3.2	7
8	Inferences About Drug Safety in PhaseÂIII Trials in Oncology: Examples From Advanced Prostate Cancer. Journal of the National Cancer Institute, 2021, 113, 553-561.	3.0	12
9	Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. Clinical Cancer Research, 2021, 27, 2087-2099.	3.2	15
10	Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2021, 39, 250-250.	0.8	0
11	Prostateâ€specific antigen nadir and testosterone level at prostateâ€specific antigen failure following radiation and androgen suppression therapy for unfavorableâ€risk prostate cancer and the risk of allâ€cause and prostate cancerâ€specific mortality. Cancer, 2021, 127, 2623-2630.	2.0	2
12	Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial.. Journal of Clinical Oncology, 2021, 39, 5011-5011.	0.8	1
13	Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care.. Journal of Clinical Oncology, 2021, 39, 6580-6580.	0.8	0
14	Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors. JAMA Oncology, 2021, 7, 720.	3.4	68
15	CD38 in Advanced Prostate Cancers. European Urology, 2021, 79, 736-746.	0.9	21
16	Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial. Journal of Clinical Oncology, 2021, 39, 2938-2947.	0.8	18
17	Reply to G. Francolini et al. Journal of Clinical Oncology, 2021, 39, 3764-3765.	0.8	1
18	Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer. Cells, 2021, 10, 2567.	1.8	1

#	Article	IF	Citations
19	Attenuation of SRC Kinase Activity Augments PARP Inhibitorâ€“mediated Synthetic Lethality in BRCA2-altered Prostate Tumors. Clinical Cancer Research, 2021, 27, 1792-1806.	3.2	13
20	Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. European Urology, 2020, 77, 158-166.	0.9	36
21	Family history of prostate cancer and the incidence of ERGâ€•and phosphatase and tensin homologâ€defined prostate cancer. International Journal of Cancer, 2020, 146, 2694-2702.	2.3	3
22	Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression. Clinical Cancer Research, 2020, 26, 2047-2064.	3.2	77
23	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clinical Cancer Research, 2020, 26, 1086-1093.	3.2	35
24	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clinical Cancer Research, 2020, 26, 6122-6131.	3.2	9
25	Racial Differences in Genomic Profiling of Prostate Cancer. New England Journal of Medicine, 2020, 383, 1083-1085.	13.9	87
26	Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cellâ€“Level PI3K Pathway Activation. Clinical Cancer Research, 2020, 26, 5903-5913.	3.2	8
27	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2020, 26, 3230-3238.	3.2	112
28	Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer. Molecular Oncology, 2020, 14, 1881-1897.	2.1	22
29	Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis, 2020, 41, 904-908.	1.3	1
30	Event-Free Survival, a Prostate-Specific Antigenâ€“Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. Journal of Clinical Oncology, 2020, 38, 3032-3041.	0.8	37
31	Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1374-1380.	1.1	57
32	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. Cancer, 2020, 126, 2935-2937.	2.0	0
33	Patterns of self-reported care in a cohort of prostate cancer survivors: Implications for risk-stratified care. Journal of Geriatric Oncology, 2020, 11, 1164-1167.	0.5	1
34	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer and Prostatic Diseases, 2020, 23, 517-526.	2.0	80
35	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
36	Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial. Cancer, 2020, 126, 3042-3052.	2.0	19

#	Article	IF	Citations
37	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. European Urology, 2020, 78, 671-679.	0.9	72
38	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precision Oncology, 2020, 4, 355-366.	1.5	93
39	TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?. Cancer Discovery, 2020, 10, 779-782.	7.7	329
40	Adverse event profiles of apalutamide, enzalutamide, and darolutamide in SPARTAN, PROSPER, and ARAMIS: How confident are we about which drug is safest?. Journal of Clinical Oncology, 2020, 38, 318-318.	0.8	9
41	A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research. OncoTargets and Therapy, 2020, Volume 13, 13247-13263.	1.0	8
42	The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer.. Journal of Clinical Oncology, 2020, 38, 149-149.	0.8	1
43	Effects of electroacupuncture and auricular acupuncture for chronic pain in cancer survivors: The PEACE randomized controlled trial.. Journal of Clinical Oncology, 2020, 38, 12004-12004.	0.8	2
44	The effect of abiraterone acetate treatment on CREB and the development of abiraterone acetate resistance in prostate cancer cells.. Journal of Clinical Oncology, 2020, 38, 177-177.	0.8	0
45	Checkpoint kinase inhibition in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors.. Journal of Clinical Oncology, 2020, 38, 150-150.	0.8	0
46	Tumor protein expression of BRCA1 and development of lethal prostate cancer.. Journal of Clinical Oncology, 2020, 38, 65-65.	0.8	0
47	Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness.. Journal of Clinical Oncology, 2020, 38, 347-347.	0.8	4
48	Association of genetic variation of the six gene prognostic model for castrationâ€resistant prostate cancer with survival. Prostate, 2019, 79, 73-80.	1.2	6
49	Realâ€world outcomes of sipuleucelâ€T treatment in PROCEED, a prospective registry of men with metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 4172-4180.	2.0	49
50	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nature Communications, 2019, 10, 4358.	5.8	109
51	Treatment of Advanced Prostate Cancer. Annual Review of Medicine, 2019, 70, 479-499.	5.0	417
52	Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy. Urology, 2019, 126, 145-151.	0.5	9
53	Methylationâ€associated miRâ€193b silencing activates master drivers of aggressive prostate cancer. Molecular Oncology, 2019, 13, 1944-1958.	2.1	17
54	Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436.	3.3	839

#	Article	IF	Citations
55	Aneuploidy drives lethal progression in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11390-11395.	3.3	101
56	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clinical Cancer Research, 2019, 25, 4290-4299.	3.2	38
57	A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clinical Cancer Research, 2019, 25, 4480-4492.	3.2	96
58	Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1052-1058.	1.1	14
59	Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. European Journal of Cancer, 2019, 112, 118-126.	1.3	36
60	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2019, 37, 1051-1061.	0.8	174
61	Impact of 5Î±â€reductase inhibitor and Î±â€blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality. BJU International, 2019, 123, 511-518.	1.3	17
62	Treatment of Metastatic Prostate Cancer in 2018. JAMA Oncology, 2019, 5, 263.	3.4	16
63	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471.	3.4	426
64	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 524-532.	2.0	8
65	Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer and Prostatic Diseases, 2019, 22, 420-427.	2.0	49
66	Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 707-714.	1.1	11
67	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. European Urology, 2019, 75, 88-99.	0.9	333
68	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.. Journal of Clinical Oncology, 2019, 37, 5035-5035.	0.8	6
69	Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes.. Journal of Clinical Oncology, 2019, 37, 5038-5038.	0.8	5
70	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).. Journal of Clinical Oncology, 2019, 37, TPS5100-TPS5100.	0.8	6
71	Targeting checkpoint kinases in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors.. Journal of Clinical Oncology, 2019, 37, e16543-e16543.	0.8	0
72	The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. Journal of Urology, 2018, 200, 344-352.	0.2	47

#	Article	IF	Citations
73	Impact of time to testosterone rebound and comorbidity on the risk of causeâ€specific mortality in men with unfavorableâ€risk prostate cancer. Cancer, 2018, 124, 1391-1399.	2.0	3
74	Current treatment strategies for advanced prostate cancer. International Journal of Urology, 2018, 25, 220-231.	0.5	164
75	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer and Prostatic Diseases, 2018, 21, 364-372.	2.0	48
76	Low testosterone at first prostateâ€specific antigen failure and assessment of risk of death in men with unfavorableâ€risk prostate cancer treated on prospective clinical trials. Cancer, 2018, 124, 1383-1390.	2.0	6
77	Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate, 2018, 78, 889-895.	1.2	111
78	The long tail of oncogenic drivers in prostate cancer. Nature Genetics, 2018, 50, 645-651.	9.4	601
79	Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer. Oncogenesis, 2018, 7, 30.	2.1	31
80	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	0.9	488
81	Prognostic Index Model for Progression-Free Survival in Chemotherapy-NaÃ¯ve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. Clinical Genitourinary Cancer, 2018, 16, 72-77.e1.	0.9	24
82	Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer. JAMA Oncology, 2018, 4, 558.	3.4	54
83	Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. Journal of Pain and Symptom Management, 2018, 55, 307-317.e1.	0.6	26
84	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	0.8	155
85	Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nature Biomedical Engineering, 2018, 2, 850-864.	11.6	214
86	Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. Journal of the Endocrine Society, 2018, 2, 485-496.	0.1	33
87	Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancerâ€“Specific Mortality. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 727-734.	2.3	2
88	A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1231-1233.	1.1	2
89	A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castrationâ€resistant prostate cancer. Prostate, 2018, 78, 1053-1062.	1.2	4
90	Regular aspirin use and gene expression profiles in prostate cancer patients. Cancer Causes and Control, 2018, 29, 775-784.	0.8	3

#	Article	IF	Citations
91	ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. Journal of Clinical Investigation, 2018, 128, 2979-2995.	3.9	53
92	Immunotherapy for biochemically recurrent prostate cancer.. Journal of Clinical Oncology, 2018, 36, 215-215.	0.8	5
93	Concurrent deletion of BRCA2 and RB1 and aggressive prostate cancer.. Journal of Clinical Oncology, 2018, 36, 241-241.	0.8	0
94	Low testosterone at first PSA failure and assessment of the risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.. Journal of Clinical Oncology, 2018, 36, 45-45.	0.8	0
95	Early versus delayed initiation of salvage androgen deprivation therapy and the risk of prostate cancer-specific mortality.. Journal of Clinical Oncology, 2018, 36, 189-189.	0.8	0
96	Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in prostate cancer.. Journal of Clinical Oncology, 2018, 36, 240-240.	0.8	0
97	Regulation of the tumor suppressor PLZF and prostate cancer prognosis.. Journal of Clinical Oncology, 2018, 36, 137-137.	0.8	0
98	Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.. Journal of Clinical Oncology, 2018, 36, 203-203.	0.8	0
99	Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 652.	3.4	41
100	The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies. Cancer, 2017, 123, 1490-1496.	2.0	6
101	Neoadjuvant Enzalutamide Prior to Prostatectomy. Clinical Cancer Research, 2017, 23, 2169-2176.	3.2	80
102	Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. Cancer Research, 2017, 77, 753-765.	0.4	31
103	The association between germline <scp>BRCA2</scp> variants and sensitivity to platinumâ€based chemotherapy among men with metastatic prostate cancer. Cancer, 2017, 123, 3532-3539.	2.0	217
104	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	3.8	366
105	Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer, 2017, 123, 4130-4138.	2.0	11
106	The impact of statin use on the efficacy of abiraterone acetate in patients with castrationâ€resistant prostate cancer. Prostate, 2017, 77, 1303-1311.	1.2	19
107	Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer, 2017, 17, 20-37.	12.8	4,153
108	Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clinical Cancer Research, 2017, 23, 726-734.	3.2	95

#	Article	IF	Citations
109	A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2017, 23, 935-945.	3.2	30
110	Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 124-125.	0.8	56
111	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	286
112	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3097-3104.	0.8	327
113	Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?. Journal of Clinical Oncology, 2017, 35, 3272-3274.	0.8	6
114	Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer. PLoS ONE, 2017, 12, e0184166.	1.1	28
115	Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight, 2016, 1, e87062.	2.3	340
116	A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer. Prostate, 2016, 76, 1338-1341.	1.2	0
117	Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. Prostate, 2016, 76, 691-699.	1.2	21
118	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	13.9	1,205
119	The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer & Metabolism, 2016, 4, 22.	2.4	26
120	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. , 2016, 4, 92.		31
121	A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. Journal of Clinical Oncology, 2016, 34, 1913-1920.	0.8	34
122	Selenium- or Vitamin Eâ€“Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1050-1058.	1.1	55
123	Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial. Journal of Clinical Oncology, 2016, 34, 3781-3786.	0.8	14
124	Physical and emotional health information needs and preferences of long-term prostate cancer survivors. Patient Education and Counseling, 2016, 99, 2049-2054.	1.0	25
125	Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer. Nature Communications, 2016, 7, 10982.	5.8	267
126	Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6Âmonths of androgen deprivation therapy for men with unfavorable-risk prostate cancer. Journal of Radiation Oncology, 2016, 5, 301-308.	0.7	0

#	Article	IF	Citations
127	Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6259-6264.	3.3	127
128	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clinical Genitourinary Cancer, 2016, 14, e299-e305.	0.9	11
129	Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 352-359.	0.8	35
130	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 2016, 34, 1402-1418.	0.8	1,089
131	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 352-359.	0.9	34
132	Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancerâ€"Reply. JAMA - Journal of the American Medical Association, 2016, 315, 1055.	3.8	3
133	Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. European Urology, 2016, 70, 549-552.	0.9	121
134	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncology, 2016, 2, 85.	3.4	86
135	Comparison of Prostate-Specific Membrane Antigenâ€"Based ¹⁸F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-NaÃ¯ve and Castration-Resistant Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 46-53.	2.8	111
136	IMAAGEN trial safety and efficacy update: Effect of abiraterone acetate and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5061-5061.	0.8	7
137	The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, 196-196.	0.8	1
138	Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer, 2015, 121, 2603-2611.	2.0	9
139	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	13.5	2,660
140	Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. Clinical Cancer Research, 2015, 21, 2591-2600.	3.2	157
141	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). Journal of the National Cancer Institute, 2015, 107, djv261.	3.0	53
142	Role of Androgen Deprivation Therapy in Early Salvage Radiation Among Patients With Prostate-Specific Antigen Level of 0.5 or Less. Clinical Genitourinary Cancer, 2015, 13, e1-e6.	0.9	19
143	Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clinical Cancer Research, 2015, 21, 3619-3630.	3.2	115
144	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. Journal of Clinical Oncology, 2015, 33, 1356-1363.	0.8	120

#	Article	IF	Citations
145	Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Human Genetics, 2015, 134, 439-450.	1.8	45
146	A Phase I Study of Everolimus and Docetaxel inÂPatients With Castration-Resistant ProstateÂCancer. Clinical Genitourinary Cancer, 2015, 13, 113-123.	0.9	33
147	Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. Journal of Urology, 2015, 194, 91-97.	0.2	62
148	GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. Clinical Genitourinary Cancer, 2015, 13, 370-377.e1.	0.9	8
149	Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncology, 2015, 1, 495.	3.4	118
150	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	1.4	128
151	Androgen Deprivation Therapy Reversibly Increases Endotheliumâ€Dependent Vasodilation in Men With Prostate Cancer. Journal of the American Heart Association, 2015, 4, .	1.6	20
152	PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy. Cancer Research, 2015, 75, 1944-1948.	0.4	46
153	The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chemico-Biological Interactions, 2015, 234, 332-338.	1.7	57
154	Identifying suicidal symptoms in prostate cancer survivors using brief self-report. Journal of Cancer Survivorship, 2015, 9, 59-67.	1.5	15
155	DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer, 2015, 15, 242.	1.1	25
156	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology, 2015, 17, 1344-1355.	0.6	40
157	Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2015, 314, 1291.	3.8	121
158	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1814-1823.	13.9	1,004
159	Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Antiâ€“Prostate Cancer Activity. Clinical Cancer Research, 2015, 21, 5578-5587.	3.2	15
160	The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nature Genetics, 2015, 47, 1346-1351.	9.4	363
161	Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Molecular Cancer Research, 2015, 13, 1431-1440.	1.5	15
162	The Role of miRNAs in Prostate Cancer. European Urology, 2015, 68, 589-590.	0.9	12

#	Article	IF	Citations
163	Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. JAMA - Journal of the American Medical Association, 2015, 314, 2077.	3.8	105
164	Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors. Clinical Cancer Research, 2015, 21, 1273-1280.	3.2	152
165	Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. European Urology, 2015, 67, 825-836.	0.9	561
166	A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.. Journal of Clinical Oncology, 2015, 33, 274-274.	0.8	6
167	Genetic variants of the organic anion transporter SLCO2B1 as pharmacogenomic determinants of response to androgen deprivation therapy (ADT) for prostate cancer.. Journal of Clinical Oncology, 2015, 33, 36-73.	0.8	1
168	Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC).. Journal of Clinical Oncology, 2015, 33, 365-365.	0.8	0
169	Statin use at the time of initiation of androgen deprivation therapy (ADT) and time to progression (TTP) in patients with hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2015, 33, 148-148.	0.8	0
170	Correlation between time to prostate cancer metastasis and overall survival after androgen-deprivation therapy initiation.. Journal of Clinical Oncology, 2015, 33, 250-250.	0.8	0
171	Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa).. Journal of Clinical Oncology, 2015, 33, 5013-5013.	0.8	1
172	(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 72-82.	1.0	16
173	Identification of ALK Gene Alterations in Urothelial Carcinoma. PLoS ONE, 2014, 9, e103325.	1.1	9
174	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. Cancer Discovery, 2014, 4, 1140-1153.	7.7	506
175	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2014, 20, 1873-1883.	3.2	63
176	Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. Prostate Cancer, 2014, 2014, 1-6.	0.4	13
177	A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T. Cancer Immunology Research, 2014, 2, 988-999.	1.6	45
178	Suicidal ideation in prostate cancer survivors: Understanding the role of physical and psychological health outcomes. Cancer, 2014, 120, 3393-3400.	2.0	49
179	FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Medicine, 2014, 3, 835-844.	1.3	76
180	The likelihood of death from prostate cancer in men with favorable or unfavorable intermediateâ€risk disease. Cancer, 2014, 120, 1787-1793.	2.0	44

#	Article	IF	Citations
181	Elevated insulinâ€like growth factor binding proteinâ€1 (IGFBPâ€1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate, 2014, 74, 225-234.	1.2	33
182	Populationâ€based patterns of prescription androgen use, 1976â€“2008. Pharmacoepidemiology and Drug Safety, 2014, 23, 498-506.	0.9	21
183	Percent positive biopsy cores and the risk of death from prostate cancer in men with unfavorable-risk prostate cancer. Journal of Radiation Oncology, 2014, 3, 307-312.	0.7	0
184	Contemporary Nationwide Patterns of Self-reported Prostate-Specific Antigen Screening. JAMA Internal Medicine, 2014, 174, 1839.	2.6	33
185	Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators. Prostate Cancer, 2014, 2014, 1-6.	0.4	5
186	Effects of a gift certificate incentive and specialized delivery on prostate cancer survivors' response rate to a mailed survey: A randomized-controlled trial. Journal of Geriatric Oncology, 2014, 5, 127-132.	0.5	10
187	Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature Biotechnology, 2014, 32, 479-484.	9.4	495
188	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine, 2014, 20, 682-688.	15.2	508
189	Elevated ILâ€8, TNFâ€Î±, and MCPâ€1 in men with metastatic prostate cancer starting androgenâ€deprivation therapy (ADT) are associated with shorter time to castrationâ€resistance and overall survival. Prostate, 2014, 74, 820-828.	1.2	66
190	SPINK1 Protein Expression and Prostate Cancer Progression. Clinical Cancer Research, 2014, 20, 4904-4911.	3.2	71
191	Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERGâ€“Positive Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2027-2031.	1.1	28
192	Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integrative Biology (United Kingdom), 2014, 6, 388-398.	0.6	51
193	Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. Journal of Clinical Oncology, 2014, 32, 3705-3715.	0.8	220
194	Development of Multinuclear Polymeric Nanoparticles as Robust Protein Nanocarriers. Angewandte Chemie - International Edition, 2014, 53, 8975-8979.	7.2	122
195	Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7319-7324.	3.3	332
196	Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib. Cancer Discovery, 2014, 4, 546-553.	7.7	266
197	Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients. Journal of Molecular Diagnostics, 2014, 16, 660-672.	1.2	70
198	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. Journal of Clinical Oncology, 2014, 32, 1889-1894.	0.8	229

#	Article	IF	Citations
199	Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study. Journal of Clinical Oncology, 2014, 32, 229-237.	0.8	70
200	Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 686-718.	2.3	294
201	Emerging players in prostate cancer: long non-coding RNAs. American Journal of Clinical and Experimental Urology, 2014, 2, 294-9.	0.4	11
202	Early Detection of Prostate Cancer: AUA Guideline. Journal of Urology, 2013, 190, 419-426.	0.2	945
203	Observation Versus Initial Treatment for Men With Localized, Low-Risk Prostate Cancer. Annals of Internal Medicine, 2013, 158, 853.	2.0	108
204	Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial. Urology, 2013, 81, 1297-1302.	0.5	211
205	Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18638-18643.	3.3	302
206	Reply to clinical predictors of survival in men with castrationâ€resistant prostate cancer. Cancer, 2013, 119, 4053-4054.	2.0	1
207	Defining the optimal approach to the patient with postradiation prostateâ€specific antigen recurrence using outcome data from a prospective randomized trial. Cancer, 2013, 119, 3280-3286.	2.0	5
208	Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncology, The, 2013, 14, 81-87.	5.1	52
209	Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunology, Immunotherapy, 2013, 62, 137-147.	2.0	225
210	Long-term Follow-up of a Phase II Trial of Chemotherapy Plus Hormone Therapy for Biochemical Relapse After Definitive Local Therapy for Prostate Cancer. Urology, 2013, 81, 611-616.	0.5	9
211	Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine, 2013, 8, 687-698.	1.7	65
212	Punctuated Evolution of Prostate Cancer Genomes. Cell, 2013, 153, 666-677.	13.5	1,107
213	Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and lowâ€risk, localized prostate cancer. Prostate, 2013, 73, 346-354.	1.2	217
214	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. Journal of the National Cancer Institute, 2013, 105, 1881-1890.	3.0	80
215	Demystifying Immunotherapy in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 50-58.	1.0	20
216	A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer. Clinical Cancer Research, 2013, 19, 1612-1619.	3.2	20

#	Article	IF	Citations
217	Clinical predictors of survival in men with castrationâ€resistant prostate cancer. Cancer, 2013, 119, 2990-2998.	2.0	35
218	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrateâ€resistant prostate cancer. Cancer, 2013, 119, 3636-3643.	2.0	17
219	New Developments in the Management of Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 653-657.	2.3	16
220	Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer.. Journal of Clinical Oncology, 2013, 31, 2-2.	0.8	0
221	Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy.. Journal of Clinical Oncology, 2013, 31, 82-82.	0.8	0
222	Smoking history and disease outcomes in patients with malignant germ cell tumors.. Journal of Clinical Oncology, 2013, 31, 4561-4561.	0.8	0
223	Neuroepithelial Tumor Arising in a Testicular Teratoma With Retroperitoneal Metastasis. Journal of Clinical Oncology, 2012, 30, e172-e174.	0.8	1
224	Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer. Journal of the National Cancer Institute, 2012, 104, 1107-1109.	3.0	32
225	Genetic and functional analyses implicate the NUDT11 , HNF1B , and SLC22A3 genes in prostate cancer pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11252-11257.	3.3	102
226	Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2012, 30, 507-512.	0.8	168
227	Prostate-Specific Antigen Test for Prostate Cancer Screening: American Society of Clinical Oncology Provisional Clinical Opinion. Journal of Oncology Practice, 2012, 8, 315-317.	2.5	9
228	New Agents in Metastatic Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1403-1409.	2.3	13
229	Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1081-1087.	2.3	208
230	Phase II trial of RAD001 and bicalutamide for castrationâ€resistant prostate cancer. BJU International, 2012, 110, 1729-1735.	1.3	71
231	EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent. Science, 2012, 338, 1465-1469.	6.0	748
232	Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncology, The, 2012, 13, 189-195.	5.1	79
233	BRAF Mutations in Metanephric Adenoma of the Kidney. European Urology, 2012, 62, 917-922.	0.9	95
234	Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men With High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1411-1416.	0.4	67

#	Article	IF	Citations
235	Posttreatment Prostate Specific Antigen Nadir Predicts Prostate Cancer Specific and All Cause Mortality. Journal of Urology, 2012, 187, 2068-2073.	0.2	21
236	Integration of immunotherapy into the management of advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, S41-S47.	0.8	11
237	Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion. Journal of Clinical Oncology, 2012, 30, 3020-3025.	0.8	128
238	The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1497-1509.	1.1	268
239	Immunotherapy for Castration-Resistant Prostate Cancer. Urologic Clinics of North America, 2012, 39, 465-481.	0.8	11
240	A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncology, The, 2012, 13, 1105-1113.	5.1	112
241	Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. Practical Radiation Oncology, 2012, 2, 172-178.	1.1	1
242	The altered expression of MiRâ€221/â€222 and MiRâ€23b/â€27b is associated with the development of human castration resistant prostate cancer. Prostate, 2012, 72, 1093-1103.	1.2	79
243	Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401. Journal of Clinical Oncology, 2012, 30, 1534-1540.	0.8	436
244	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics, 2012, 44, 685-689.	9.4	1,300
245	Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile. Science Translational Medicine, 2012, 4, 128ra39.	5.8	978
246	Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with highâ€risk localized prostate cancer. Cancer, 2012, 118, 4777-4784.	2.0	46
247	The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature. European Urology, 2012, 61, 639-647.	0.9	28
248	Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. BJU International, 2012, 110, 1252-1256.	1.3	5
249	Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane.. Journal of Clinical Oncology, 2012, 30, 107-107.	0.8	1
250	Use of elevated baseline IL-8, CCL-2, and TNFÎ± to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT).. Journal of Clinical Oncology, 2012, 30, 13-13.	0.8	0
251	Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT).. Journal of Clinical Oncology, 2012, 30, 191-191.	0.8	0
252	Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opinion on Biological Therapy, 2011, 11, 997-1009.	1.4	20

#	Article	IF	Citations
253	Immunotherapy for the treatment of prostate cancer. Nature Reviews Clinical Oncology, 2011, 8, 551-561.	12.5	86
254	Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancerâ€“Specific Mortality. Cancer Prevention Research, 2011, 4, 719-728.	0.7	48
255	Singleâ€nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU International, 2011, 107, 126-134.	1.3	36
256	Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU International, 2011, 108, 1086-1091.	1.3	9
257	The genomic complexity of primary human prostate cancer. Nature, 2011, 470, 214-220.	13.7	1,107
258	Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2011, 9, 95-103.	0.9	15
259	Elevated plasma tissue inhibitor of metalloproteinaseâ€1 levels predict decreased survival in castrationâ€resistant prostate cancer patients. Cancer, 2011, 117, 517-525.	2.0	35
260	Risk of All-Cause and Prostate Cancerâ€“Specific Mortality After Brachytherapy in Men With Small Prostate Size. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1318-1322.	0.4	11
261	Vitamin D Receptor Protein Expression in Tumor Tissue and Prostate Cancer Progression. Journal of Clinical Oncology, 2011, 29, 2378-2385.	0.8	130
262	Duration of Short-Course Androgen Suppression Therapy and the Risk of Death As a Result of Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 4682-4687.	0.8	17
263	Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort. Clinical Cancer Research, 2011, 17, 1546-1552.	3.2	19
264	Prostate Cancer Immunotherapy: Figure 1.. Clinical Cancer Research, 2011, 17, 5233-5238.	3.2	57
265	mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 2391-2396.	0.8	140
266	The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness. Cancer Prevention Research, 2011, 4, 2044-2050.	0.7	27
267	Prospective Evaluation of Analgesic Use and Risk of Renal Cell Cancer. Archives of Internal Medicine, 2011, 171, 1487.	4.3	59
268	SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 2565-2573.	0.8	153
269	TREATMENT OF PROSTATE CANCER â€" HORMONAL THERAPY. , 2011, , 519-557.		0
270	Activity of ketoconazole after taxaneâ€based chemotherapy in castrationâ€resistant prostate cancer. BJU International, 2010, 105, 1392-1396.	1.3	24

#	Article	IF	Citations
271	Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer. JAMA - Journal of the American Medical Association, 2010, 304, 2373.	3.8	232
272	Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 162-200.	2.3	671
273	Comorbidity, body mass index, and age and the risk of nonprostateâ€cancerâ€specific mortality after a postradiation prostateâ€specific antigen recurrence. Cancer, 2010, 116, 610-615.	2.0	11
274	Survival Following Radiation and Androgen Suppression Therapy for Prostate Cancer in Healthy Older Men: Implications for Screening Recommendations. International Journal of Radiation Oncology Biology Physics, 2010, 76, 337-341.	0.4	17
275	Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1046-1052.	0.4	42
276	Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Medical Genomics, 2010, 3, 8.	0.7	219
277	Sipuleucel-T. Nature Reviews Drug Discovery, 2010, 9, 513-514.	21.5	134
278	Immunohistochemical Expression of BRCA1 and Lethal Prostate Cancer. Cancer Research, 2010, 70, 3136-3139.	0.4	110
279	Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy. Journal of Clinical Oncology, 2010, 28, 1481-1488.	0.8	369
280	Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 1099-1105.	0.8	900
281	Genome-wide Association Study of Prostate Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2869-2876.	1.1	46
282	A Large Prospective Study of SEP15 Genetic Variation, Interaction with Plasma Selenium Levels, and Prostate Cancer Risk and Survival. Cancer Prevention Research, 2010, 3, 604-610.	0.7	79
283	Inherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1871-1878.	1.1	19
284	Changes In PSA Kinetics After DNA Vaccine Therapyâ€"Not So Fast!. Journal of Clinical Oncology, 2010, 28, e58-e58.	0.8	4
285	Reply to L. LeÃ³n et al. Journal of Clinical Oncology, 2010, 28, e417-e417.	0.8	0
286	Reply to M. Kumar et al. Journal of Clinical Oncology, 2010, 28, e447-e447.	0.8	1
287	Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population. Clinical Cancer Research, 2010, 16, 5244-5251.	3.2	35
288	Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis. PLoS Genetics, 2010, 6, e1001204.	1.5	82

#	Article	IF	Citations
289	Predictors of survival in patients with prostate cancer and spinal metastasis. Journal of Neurosurgery: Spine, 2010, 13, 789-794.	0.9	34
290	ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine, 2010, 5, 361-368.	1.7	95
291	Genomic Evaluation and Management of Prostate Cancer. , 2010, , 477-492.		0
292	Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2010, 363, 411-422.	13.9	4,724
293	Cancer of the Genitourinary Tract. , 2010, , 233-277.		0
294	Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 3577-3583.	0.8	69
295	Evaluating the Combined Effect of Comorbidity and Prostate-Specific Antigen Kinetics on the Risk of Death in Men After Prostate-Specific Antigen Recurrence. Journal of Clinical Oncology, 2009, 27, 6000-6005.	0.8	17
296	Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2009, 15, 7099-7105.	3.2	75
297	Role of microRNA-221/-222 in cancer development and progression. Cell Cycle, 2009, 8, 2315-2316.	1.3	25
298	Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality. Clinical Cancer Research, 2009, 15, 3223-3230.	3.2	46
299	Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression. Cancer Research, 2009, 69, 5568-5574.	0.4	110
300	Activity of Dutasteride Plus Ketoconazole in Castration-Refractory Prostate Cancer After Progression on Ketoconazole Alone. Clinical Genitourinary Cancer, 2009, 7, E90-E92.	0.9	18
301	Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. International Journal of Cancer, 2009, 125, 1143-1146.	2.3	9
302	Time to prostateâ€specific antigen nadir independently predicts overall survival in patients who have metastatic hormoneâ€sensitive prostate cancer treated with androgenâ€deprivation therapy. Cancer, 2009, 115, 981-987.	2.0	116
303	Interval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death. International Journal of Radiation Oncology Biology Physics, 2009, 75, 10-15.	0.4	42
304	Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer. Cell, 2009, 138, 245-256.	13.5	797
305	Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. Clinical Genitourinary Cancer, 2009, 7, 51-57.	0.9	21
306	The Role of microRNA-221 and microRNA-222 in Androgen-Independent Prostate Cancer Cell Lines. Cancer Research, 2009, 69, 3356-3363.	0.4	236

#	Article	IF	Citations
307	Clinical Progression to Castration-Recurrent Prostate Cancer. , 2009, , 57-72.		1
308	Screening for Prostate Cancer. New England Journal of Medicine, 2009, 360, e18.	13.9	11
309	Androgen receptor mediates the expression of UDPâ€glucuronosyltransferase 2 B15 and B17 genes. Prostate, 2008, 68, 839-848.	1.2	67
310	Superparamagnetic Iron Oxide Nanoparticleâ€“Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy. ChemMedChem, 2008, 3, 1311-1315.	1.6	297
311	Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer. Cancer, 2008, 112, 1247-1253.	2.0	107
312	Active surveillance for earlyâ€stage prostate cancer. Cancer, 2008, 112, 1650-1659.	2.0	252
313	Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer, 2008, 113, 3290-3297.	2.0	35
314	Response to docetaxel/carboplatinâ€based chemotherapy as firstâ€and secondâ€line therapy in patients with metastatic hormoneâ€refractory prostate cancer. BJU International, 2008, 101, 308-312.	1.3	43
315	A phase II study of mifepristone (RUâ€486) in castrationâ€resistant prostate cancer, with a correlative assessment of androgenâ€related hormones. BJU International, 2008, 101, 1084-1089.	1.3	68
316	Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time. Journal of Urology, 2008, 179, 2181-2186.	0.2	122
317	p53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology, 2008, 71, 933-937.	0.5	21
318	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 2008, 26, 1148-1159.	0.8	1,960
319	Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer. Journal of Clinical Oncology, 2008, 26, 842-847.	0.8	100
320	Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 249-251.	1.1	12
321	Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1682-1688.	1.1	19
322	Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. Journal of the National Cancer Institute, 2008, 100, 815-825.	3.0	286
323	Risk of Prostate Cancer Recurrence in Men Treated With Radiation Alone or in Conjunction With Combined or Less Than Combined Androgen Suppression Therapy. Journal of Clinical Oncology, 2008, 26, 2979-2983.	0.8	56
324	Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer. Journal of Clinical Oncology, 2008, 26, 2544-2549.	0.8	173

#	Article	IF	Citations
325	Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 289-95.	3.8	612
326	Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?. Nature Reviews Urology, 2008, 5, 80-81.	1.4	1
327	Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions. Journal of Clinical Oncology, 2007, 25, 2420-2425.	0.8	475
328	Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data. Bioinformatics, 2007, 23, 1451-1458.	1.8	12
329	Aspirin and Hormone Therapy for Prostate Cancer. New England Journal of Medicine, 2007, 357, 2737-2738.	13.9	8
330	Prostate Cancer Risk and ESR1 TA, ESR2 CA Repeat Polymorphisms. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2233-2236.	1.1	30
331	Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonistâ€“Induced Bone Loss in Men With Prostate Cancer. Journal of Clinical Oncology, 2007, 25, 1038-1042.	0.8	303
332	Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study. Clinical Cancer Research, 2007, 13, 2030-2037.	3.2	85
333	Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma. Journal of Immunotherapy, 2007, 30, 749-761.	1.2	114
334	Bone Directed Therapies for Prostate Cancer. Journal of Urology, 2007, 178, S42-8.	0.2	10
335	Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer. Journal of Urology, 2007, 177, 2146-2150.	0.2	23
336	Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment. Journal of Urology, 2007, 178, S14-9.	0.2	368
337	Predicting Outcomes in Prostate Cancer: How Many More Nomograms Do We Need?. Journal of Clinical Oncology, 2007, 25, 3563-3564.	0.8	38
338	GENETIC DETERMINANTS OF PROSTATE CANCER RISK. BJU International, 2007, 100, 241-243.	1.3	6
339	PROSTATE-SPECIFIC ANTIGEN SCREENING FOR PROSTATE CANCER: A DECISION-ANALYTICAL PERSPECTIVE. BJU International, 2007, 100, 486-488.	1.3	2
340	Quantum Dotâ^'Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer. Nano Letters, 2007, 7, 3065-3070.	4.5	950
341	Advances in the Treatment of Prostate Cancer. Annual Review of Medicine, 2007, 58, 205-220.	5.0	30
342	Attempts at Gene Therapy in Î²-Thalassemic Mice. Annals of the New York Academy of Sciences, 2006, 445, 445-451.	1.8	13

#	Article	IF	Citations
343	Prognostic Significance of Plasma Scatter Factor/Hepatocyte Growth Factor Levels in Patients with Metastatic Hormone- Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 150005/9480. Clinical Genitourinary Cancer, 2006, 4, 269-274.	0.9	38
344	Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology, 2006, 67, 1235-1240.	0.5	53
345	Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics, 2006, 61, 401-8.	0.6	35
346	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6315-6320.	3.3	1,595
347	Development of an Integrated Prostate Cancer Research Information System. Clinical Genitourinary Cancer, 2006, 5, 61-66.	0.9	56
348	Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer, 2006, 107, 530-535.	2.0	43
349	Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer, 2006, 107, 975-981.	2.0	42
350	The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis, 2006, 27, 599-605.	1.3	32
351	Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising Serum Prostate-Specific Antigen After Radical Prostatectomy and/or Radiation Therapy. Journal of Clinical Oncology, 2006, 24, 2723-2728.	0.8	123
352	Noise and Bias in Microarray Analysis of Tumor Specimens. Journal of Clinical Oncology, 2006, 24, 3719-3721.	0.8	19
353	Application of Oligonucleotide Microarrays to Assess the Biological Effects of Neoadjuvant Imatinib Mesylate Treatment for Localized Prostate Cancer. Clinical Cancer Research, 2006, 12, 152-158.	3.2	27
354	Carboplatin for Stage I Seminoma. Journal of Clinical Oncology, 2006, 24, 2971-2972.	0.8	5
355	Prevention, complementary therapies, and new scientific developments in the field of prostate cancer. Reviews in Urology, 2006, 8 Suppl 2, S9-S14.	0.9	1
356	Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU International, 2005, 96, 783-786.	1.3	27
357	The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480. Clinical Cancer Research, 2005, 11, 1815-1820.	3.2	152
358	Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer. Clinical Cancer Research, 2005, 11, 5233-5240.	3.2	167
359	Prognostic Significance of Baseline Reverse Transcriptase-PCR for Prostate-Specific Antigen in Men with Hormone-Refractory Prostate Cancer Treated with Chemotherapy. Clinical Cancer Research, 2005, 11, 5195-5198.	3.2	14
360	Decreased Â-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1424-1432.	1.1	105

#	Article	IF	Citations
361	p63 regulates commitment to the prostate cell lineage. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11355-11360.	3.3	134
362	Manganese Superoxide Dismutase Polymorphism, Prediagnostic Antioxidant Status, and Risk of Clinical Significant Prostate Cancer. Cancer Research, 2005, 65, 2498-2504.	0.4	210
363	Prediagnostic Plasma Vascular Endothelial Growth Factor Levels and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1557-1561.	1.1	16
364	Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancerâ€"A Cancer and Leukemia Group B Study. Clinical Cancer Research, 2005, 11, 8109-8113.	3.2	27
365	Autoantibody Signatures in Prostate Cancer. New England Journal of Medicine, 2005, 353, 1224-1235.	13.9	581
366	Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology, 2005, 66, 386-391.	0.5	89
367	Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1262-1269.	1.1	212
368	A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clinical Cancer Research, 2005, 11, 284-9.	3.2	22
369	Recent progress in management of advanced prostate cancer. Oncology, 2005, 19, 631-6.	0.4	12
370	A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer. Clinical Cancer Research, 2004, 10, 924-928.	3.2	71
371	6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2004, 292, 821.	3.8	713
372	Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer. Journal of Clinical Oncology, 2004, 22, 3705-3712.	0.8	114
373	Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group. Journal of Clinical Oncology, 2004, 22, 537-556.	0.8	189
374	Genotyping and functional analysis of the D104N variant of human endostatin. Cancer Biology and Therapy, 2004, 3, 1298-1303.	1.5	13
375	Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer, 2004, 101, 1569-1574.	2.0	126
376	Effect of finasteride on risk of prostate cancer: How little we really know. Journal of Cellular Biochemistry, 2004, 91, 478-482.	1.2	13
377	Feasibility of Radical Prostatectomy After Neoadjuvant Chemohormonal Therapy for Patients With High Risk or Locally Advanced Prostate Cancer: Results of a Phase I/II Study. Journal of Urology, 2004, 171, 709-713.	0.2	83
378	FOURTH INTERNATIONAL CONFERENCE ON INNOVATIONS AND CHALLENGES IN PROSTATE CANCER: PREVENTION, DETECTION AND TREATMENT. Journal of Urology, 2004, 172, S3-5.	0.2	4

#	Article	IF	Citations
379	Absence of a Correlation of Androgen Receptor Gene CAG Repeat Length and Prostate Cancer Risk in an African-American Population. Clinical Prostate Cancer, 2004, 3, 98-103.	2.1	32
380	Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology, 2004, 63, 327-332.	0.5	27
381	Racial Differences in Screening for Prostate Cancer in the Elderly. Archives of Internal Medicine, 2004, 164, 1858.	4.3	97
382	Opportunities for Targeted Molecular Therapy for Prostate Cancer. , 2004, , 631-652.		0
383	Differentiating agents and the treatment of prostate cancer: vitamin D and peroxisome proliferator-activated receptor gamma ligands. Seminars in Oncology, 2003, 30, 698-708.	0.8	14
384	Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. Cancer, 2003, 97, 2171-2179.	2.0	10
385	Male Patients with Diagnoses of Both Breast Cancer and Prostate Cancer. Breast Journal, 2003, 9, 208-212.	0.4	16
386	Third International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. Journal of Urology, 2003, 170, S3-5.	0.2	5
387	Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology, 2003, 62, 99-104.	0.5	23
388	Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology, 2003, 62, 324-327.	0.5	99
389	Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer. Journal of Clinical Oncology, 2003, 21, 1232-1237.	0.8	646
390	Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663. Journal of Clinical Oncology, 2003, 21, 2673-2678.	0.8	343
391	Prognostic Significance of Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen in Metastatic Prostate Cancer: A Nested Study Within CALGB 9583. Journal of Clinical Oncology, 2003, 21, 490-495.	0.8	54
392	The Ingredients for Prostate Cancer Nomograms: The Addition of Biomarkers Sets the Table for Future Recipes. Journal of Clinical Oncology, 2003, 21, 3552-3553.	0.8	4
393	Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7841-7846.	3.3	282
394	Chemotherapy for Teratoma With Malignant Transformation. Journal of Clinical Oncology, 2003, 21, 4285-4291.	0.8	211
395	Time Course and Predictors of Symptoms After Primary Prostate Cancer Therapy. Journal of Clinical Oncology, 2003, 21, 3979-3986.	0.8	196
396	Prevention of Prostate Cancer with Finasteride. New England Journal of Medicine, 2003, 349, 1569-1572.	13.9	18

#	Article	IF	Citations
397	Title is missing!. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 312-316.	0.6	3
398	Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Research, 2003, 63, 4781-5.	0.4	100
399	A Phase II Trial of Interferon-Alpha and Toremifene in Advanced Renal Cell Cancer Patients. Cancer Investigation, 2002, 20, 186-191.	0.6	4
400	Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 599-603.	1.8	597
401	ATAAA repeat upstream of glutathione S-transferase P1 and prostate cancer risk. Urology, 2002, 59, 159-164.	0.5	6
402	Overview consensus statement. Urology, 2002, 60, 1-6.	0.5	33
403	Chemotherapy for prostate cancer. Urology, 2002, 60, 94-100.	0.5	108
404	Gene expression correlates of clinical prostate cancer behavior. Cancer Cell, 2002, 1, 203-209.	7.7	2,144
405	PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER. Journal of Urology, 2002, 167, 1392-1392.	0.2	7
406	Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma. Cancer, 2002, 94, 686-689.	2.0	12
407	Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer, 2002, 95, 275-280.	2.0	22
408	Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer, 2002, 95, 1864-1868.	2.0	49
409	Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Investigational New Drugs, 2002, 20, 195-200.	1.2	24
410	CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Research, 2002, 62, 5517-5522.	0.4	68
411	Other novel agents: Rationale and current status as chemopreventive agents. Urology, 2001, 57, 86-89.	0.5	14
412	Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology, 2001, 57, 122-126.	0.5	70
413	Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer. Journal of Clinical Oncology, 2001, 19, 44-53.	0.8	182
414	Prognostic Significance of Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen in Men With Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 2001, 19, 3025-3028.	0.8	52

#	Article	IF	Citations
415	Low bone mineral density in hormone-naï¿½ve men with prostate carcinoma. Cancer, 2001, 91, 2238-2245.	2.0	130
416	Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine, 2001, 345, 948-955.	13.9	669
417	Low bone mineral density in hormone-naÃ¯ve men with prostate carcinoma. , 2001, 91, 2238.		1
418	Amplified in Breast Cancerâ€1 Glutamine Repeat and Prostate Cancerâ€ƒRisk. Prostate Journal, 2000, 2, 27-32.	0.2	14
419	HRAS1 Proto-Oncogene Polymorphism and Prostate Cancer. Prostate Journal, 2000, 2, 211-218.	0.2	0
420	Utilizing Predictions of Early Prostate-Specific Antigen Failure to Optimize Patient Selection for Adjuvant Systemic Therapy Trials. Journal of Clinical Oncology, 2000, 18, 3240-3246.	0.8	44
421	Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer. Journal of the National Cancer Institute, 2000, 92, 1918-1925.	3.0	323
422	Case 1-2000. New England Journal of Medicine, 2000, 342, 115-122.	13.9	10
423	Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma. Urology, 2000, 55, 31-35.	0.5	26
424	Treatment of Locally Advanced Prostate Cancer: Is Chemotherapy the Next Step?. Journal of Clinical Oncology, 1999, 17, 3664-3675.	0.8	36
425	Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study. Journal of Clinical Oncology, 1999, 17, 2506-2506.	0.8	853
426	Antiandrogens in prostate cancer. Investigational New Drugs, 1999, 17, 271-284.	1.2	53
427	Phase II Trial of the Antiestrogen Toremifene for Androgen-Independent Prostate Cancer. Prostate Journal, 1999, 1, 185-189.	0.2	1
428	A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. , 1999, 86, 1329-1334.		6
429	CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. , 1999, 39, 130-134.		63
430	Modification of BRCA1-Associated Breast Cancer Risk by the Polymorphic Androgen-Receptor CAG Repeat. American Journal of Human Genetics, 1999, 64, 1371-1377.	2.6	219
431	The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology, 1999, 53, 121-125.	0.5	114
432	Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology, 1999, 54, 523-527.	0.5	245

#	Article	IF	Citations
433	Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology, 1999, 54, 1064-1067.	0.5	104
434	PROGNOSTIC INDICATORS IN HORMONE REFRACTORY PROSTATE CANCER. Urologic Clinics of North America, 1999, 26, 303-310.	0.8	25
435	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS. Journal of Urology, 1998, 160, 1220-1229.	0.2	221
436	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER. Journal of Urology, 1998, , 1220-1229.	0.2	12
437	Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology, 1997, 49, 913-920.	0.5	81
438	Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology, 1997, 50, 100-105.	0.5	64
439	Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma. Urology, 1996, 48, 741-746.	0.5	8
440	Regulation of S100P expression by androgen. , 1996, 29, 350-355.		71
441	Nonpalpable Intratesticular Masses Detected Sonographically. Journal of Urology, 1995, 154, 1367-1369.	0.2	77
442	Rate of relapse following treatment for localized prostate cancer: A critical analysis of retrospective reports. International Journal of Radiation Oncology Biology Physics, 1994, 28, 303-313.	0.4	21
443	Meningeal carcinomatosis from transitional cell carcinoma of the bladder. Cancer, 1993, 72, 553-557.	2.0	30
444	Synchronous Adenocarcinoma and Transitional Cell Carcinoma of the Bladder Associated with Augmentation: Case Report And Review of the Literature. Journal of Urology, 1993, 149, 115-118.	0.2	51
445	Hormonal perturbations in patients with testicular cancer treated with cisplatin. Cancer, 1992, 69, 2306-2310.	2.0	19
446	Gene Therapy: Efforts at Developing Large Animal Models for Autologous Bone Marrow Transplant and Gene Transfer with Retroviral Vectors. Novartis Foundation Symposium, 1987, 130, 229-246.	1.2	1
447	Histologic Demonstration of Intradermal Spirochetes in a Patient with Lyme Disease. American Journal of the Medical Sciences, 1984, 287, 40-42.	0.4	5